Achieving blood lipid goals in patients with coronary artery disease

American Journal of Health-System Pharmacy

Volumn 58, Issue 5, 2001, Pages 415-419

  McKenney, J M ^a  

^a National Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FOLLOW UP; HEALTH CARE QUALITY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0035282481     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.5.415     Document Type: Note

References (38)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
5. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
6. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study: Attainment of goals for comprehensive risk reduction in patients with coronary disease in the US
7. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles
8. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
9. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
10. Elucidation of the role of plaque instability and rupture in acute coronary events
11. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study
12. Diet, lipoproteins, and the progression of coronary atherosclerosis: The Leiden Intervention Trial
13. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: A seven-year prospective angiographic study
14. The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
15. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
16. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
17. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
18. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
19. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
20. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?
21. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial
22. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease
23. Beneficial effects of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients
24. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
25. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
26. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
27. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
28. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
29. Is use of a statin agent at the time of presentation for acute myocardial infarction associated with a favorable outcome?
30. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
31. Atherosclerosis: Basic mechanisms - Oxidation, inflammation, and genetics
32. Molecular basis of acute coronary syndromes
33. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
34. Long-term effects of pravastatin on plasma concentration of C-reactive protein
35. Early HMG-COA reductase inhibition in acute coronary syndromes: Preliminary data of the Pravastatin in Acute Ischaemic Syndromes Study (PAIS)
36. The decisive importance of cholestererol lowering therapy for coronary, lesions and clinical course immediately after an acute coronary event: Short and longterm results of a controlled study
37. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
38. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease